Bio4t2
Pre-clinicalBio4t2, clinical stage company uses PrismCore platform to genetically modify T cells to express CARs tuned to recognize self-antigens overexpressed on solid tumors.
Market Cap
Private
Pipeline
—
Patents
—
Publications
—
Private Company
Total funding raised: $4.3M
About
Bio4t2, clinical stage company uses PrismCore platform to genetically modify T cells to express CARs tuned to recognize self-antigens overexpressed on solid tumors.
Cell & Gene Therapy
Funding History
2Total raised:$4.3M
Grant$1.8MMay 15, 2022
Seed$2.5MMar 15, 2021